IP Verse

Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound

Patent No. EP3578175 (titled "Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound") was filed by Amgen on Sep 10, 2004. The application was issued on Nov 30, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BIOGARANAug 30, 2023CASALONGA
GLENMARK PHARMACEUTICALS EUROPEAug 30, 2023SCHLICH
TAD PHARMAAug 30, 2023HOEFER & PARTNER PATENTANWALTE MBB
ARROW GENERIQUES PUREN PHARMAAug 29, 2023HAMM & WITTKOPP
ELKINGTON AND FIFEAug 29, 2023ELKINGTON AND FIFE
SANDOZAug 29, 2023MAIWALD
HAMM & WITTKOPPAug 24, 2023HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3578175

AMGEN
Application Number
EP19164145A
Filing Date
Sep 10, 2004
Status
Revoked
Feb 21, 2025
Publication Date
Nov 30, 2022
External Links
Slate, Register , Google Patents